Yingxi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yingxi Xu has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Jianxiang Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
15 shared publications - Qing Rao
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
10 shared publications Min Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
9 shared publications- Ping-Chih Ho
Department of Oncology, University of Lausanne, Lausanne, Switzerland
9 shared publications - Chen Wang
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
6 shared publications - Hai-Yan Xing
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
6 shared publications
Latest Publications
- 13 November 2026
- Published by Springer Nature in Nature Immunology
Rewiring dendritic cell function with CLEC9A and DEC205 CARs
- 13 November 2026
- Published by Springer Nature in Nature Immunology
Rewiring dendritic cell function with CLEC9A and DEC205 CARs
- Open Access
- 29 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8136) , E5
Author Correction: Proteasome-guided haem signalling axis contributes to T cell exhaustion
- 29 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8136) , E5
Open AccessAuthor Correction: Proteasome-guided haem signalling axis contributes to T cell exhaustion
- 7 May 2026
- Published by Springer Nature in Nature
- Vol. 653 (8115) , E11
Author Correction: Proteasome-guided haem signalling axis contributes to T cell exhaustion
- 7 May 2026
- Published by Springer Nature in Nature
- Vol. 653 (8115) , E11
Author Correction: Proteasome-guided haem signalling axis contributes to T cell exhaustion
- Top Cited PapersOpen Access
- 18 March 2026
- Published by Springer Nature in Nature
- Vol. 653 (8114) , 548-557
Proteasome-guided haem signalling axis contributes to T cell exhaustion
The accumulation of depolarized mitochondria commits T cells to exhaustion 1–3 , yet the precise mechanism remains unclear. Here we find that exhausted CD8 + T cells increase proteasome activity owing to the accumulation of depolarized mitochondria, which drives the selective degradation of mitochondrial proteins and the release of regulatory haem through haemoprotein breakdown. In turn, increased regulatory haem disrupts BACH2-mediated transcriptional regulation, thereby exacerbating T cell exhaustion and compromising stemness-like properties. Inhibition of nuclear import of regulatory haem prevents BACH2 degradation and enhances the anti-tumour efficacy of antigen-specific T cells. We find that the therapeutic efficacy of human CD19 + chimeric antigen receptor (CAR)-T cells in patients with B cell acute lymphoblastic leukaemia negatively correlates with the proteasome gene signature in their CAR-T cells. Manufacturing CAR-T cells in the presence of bortezomib, an FDA-approved proteasome inhibitor, prevents T cell exhaustion and improves therapeutic efficacy. Our findings identify a proteasome-guided haem signalling axis, governed by mitochondrial integrity, as a regulator of CD8 + T cell exhaustion and propose innovative therapeutic strategies that exploit this pathway to optimize adoptive cellular immunotherapy.
- 18 March 2026
- Published by Springer Nature in Nature
- Vol. 653 (8114) , 548-557
Top Cited PapersOpen AccessProteasome-guided haem signalling axis contributes to T cell exhaustion
The accumulation of depolarized mitochondria commits T cells to exhaustion 1–3 , yet the precise mechanism remains unclear. Here we find that exhausted CD8 + T cells increase proteasome activity owing to the accumulation of depolarized mitochondria, which drives the selective degradation of mitochondrial proteins and the release of regulatory haem through haemoprotein breakdown. In turn, increased regulatory haem disrupts BACH2-mediated transcriptional regulation, thereby exacerbating T cell exhaustion and compromising stemness-like properties. Inhibition of nuclear import of regulatory haem prevents BACH2 degradation and enhances the anti-tumour efficacy of antigen-specific T cells. We find that the therapeutic efficacy of human CD19 + chimeric antigen receptor (CAR)-T cells in patients with B cell acute lymphoblastic leukaemia negatively correlates with the proteasome gene signature in their CAR-T cells. Manufacturing CAR-T cells in the presence of bortezomib, an FDA-approved proteasome inhibitor, prevents T cell exhaustion and improves therapeutic efficacy. Our findings identify a proteasome-guided haem signalling axis, governed by mitochondrial integrity, as a regulator of CD8 + T cell exhaustion and propose innovative therapeutic strategies that exploit this pathway to optimize adoptive cellular immunotherapy.
- Open Access
- 18 February 2026
- Published by Springer Nature in Research Square
Rewiring dendritic cell function with CLEC9A and DEC205-based chimeric antigen receptors
Dendritic cells (DCs) are central orchestrators of anti-tumor immunity, yet their therapeutic utility has been limited by dysfunction and insufficient activation within solid tumors. Here, we report chimeric antigen receptor-engineered DCs (CAR-DCs) that potently prime T cells and reprogram the tumor microenvironment. We identify the intracellular domains of CLEC9A or DEC205 as essential for functional CAR-DC activity, enabling enhanced antigen uptake, cross-presentation, and robust cytokine production that drive strong T cell expansion and effector differentiation. Mechanistically, CARs incorporating CLEC9A or DEC205 intracellular domains triggered SYK phosphorylation and downstream signaling pathways. In both murine and humanized models, CAR-DC therapy suppressed tumor growth and promoted expansion of tumor-reactive T cells. These findings establish CAR-DCs as a scalable and clinically translatable platform for next-generation solid tumor immunotherapy.
- 18 February 2026
- Published by Springer Nature in Research Square
Open AccessRewiring dendritic cell function with CLEC9A and DEC205-based chimeric antigen receptors
Dendritic cells (DCs) are central orchestrators of anti-tumor immunity, yet their therapeutic utility has been limited by dysfunction and insufficient activation within solid tumors. Here, we report chimeric antigen receptor-engineered DCs (CAR-DCs) that potently prime T cells and reprogram the tumor microenvironment. We identify the intracellular domains of CLEC9A or DEC205 as essential for functional CAR-DC activity, enabling enhanced antigen uptake, cross-presentation, and robust cytokine production that drive strong T cell expansion and effector differentiation. Mechanistically, CARs incorporating CLEC9A or DEC205 intracellular domains triggered SYK phosphorylation and downstream signaling pathways. In both murine and humanized models, CAR-DC therapy suppressed tumor growth and promoted expansion of tumor-reactive T cells. These findings establish CAR-DCs as a scalable and clinically translatable platform for next-generation solid tumor immunotherapy.
- Open Access
- 23 September 2025
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 37 (5) , 440-453
CD8+ T cell stressors converge on shared metabolic–epigenetic networks
- 23 September 2025
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 37 (5) , 440-453
Open AccessCD8+ T cell stressors converge on shared metabolic–epigenetic networks
- 16 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (9)
Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophages
In the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) play a crucial role in promoting tumor progression by creating an immunosuppressive environment through cytokine secretion and antigen presentation. While previous studies have demonstrated that CAFs exhibit distinct metabolic profiles compared with normal fibroblasts, it remains unclear how these metabolic programs influence the immune landscape within tumors and which factors drive metabolic reprogramming in CAFs. Here, we found that glutamine synthesis by CAFs promotes the polarization of pro-tumorigenic tumor-associated macrophages (TAMs) and supports tumor growth by altering TAM composition, highlighting the pivotal role of CAFs in shaping the immunosuppressive TME. Mechanistically, we found that tumor-derived palmitic acid activates a signaling cascade involving TLR4, Syk, and NF-κB in fibroblasts, leading to inflammatory CAF polarization and IL-6–induced glutamine synthesis. These findings uncover a novel metabolic symbiosis whereby tumor cells manipulate TAM polarization through CAF-mediated glutamine metabolism, presenting potential therapeutic targets for cancer immunotherapy.
- 16 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (9)
Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophages
In the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) play a crucial role in promoting tumor progression by creating an immunosuppressive environment through cytokine secretion and antigen presentation. While previous studies have demonstrated that CAFs exhibit distinct metabolic profiles compared with normal fibroblasts, it remains unclear how these metabolic programs influence the immune landscape within tumors and which factors drive metabolic reprogramming in CAFs. Here, we found that glutamine synthesis by CAFs promotes the polarization of pro-tumorigenic tumor-associated macrophages (TAMs) and supports tumor growth by altering TAM composition, highlighting the pivotal role of CAFs in shaping the immunosuppressive TME. Mechanistically, we found that tumor-derived palmitic acid activates a signaling cascade involving TLR4, Syk, and NF-κB in fibroblasts, leading to inflammatory CAF polarization and IL-6–induced glutamine synthesis. These findings uncover a novel metabolic symbiosis whereby tumor cells manipulate TAM polarization through CAF-mediated glutamine metabolism, presenting potential therapeutic targets for cancer immunotherapy.
- Open Access
- 29 May 2025
- Published by Oxford University Press (OUP) in Life Metabolism
- Vol. 4 (4) , loaf018
Circadian metabolism in myeloid cells
Circadian rhythms are fundamental regulators of physiological processes, including immune function. Recent insights uncover that not only lymphocytes but also myeloid cells possess intrinsic circadian clocks that govern their behavior and function. Emerging evidence highlights how circadian regulation of metabolism critically shapes the inflammatory and tissue-repair functions of myeloid subsets. Furthermore, mitochondrial dynamics, a key metabolic feature, are under circadian control and influence antigen presentation and effector functions. Here, we review the interplay between circadian clocks, metabolism, and myeloid immunity, discussing their therapeutic opportunities for optimizing vaccination, infection management, and immunotherapy.
- 29 May 2025
- Published by Oxford University Press (OUP) in Life Metabolism
- Vol. 4 (4) , loaf018
Open AccessCircadian metabolism in myeloid cells
Circadian rhythms are fundamental regulators of physiological processes, including immune function. Recent insights uncover that not only lymphocytes but also myeloid cells possess intrinsic circadian clocks that govern their behavior and function. Emerging evidence highlights how circadian regulation of metabolism critically shapes the inflammatory and tissue-repair functions of myeloid subsets. Furthermore, mitochondrial dynamics, a key metabolic feature, are under circadian control and influence antigen presentation and effector functions. Here, we review the interplay between circadian clocks, metabolism, and myeloid immunity, discussing their therapeutic opportunities for optimizing vaccination, infection management, and immunotherapy.
- 9 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (107) , eadm8186
Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-γ
Neutralizing anti–interferon-γ (IFN-γ) autoantibodies (nAIGAs) impair IFN-γ–mediated immunity, predisposing patients with nAIGAs to infection by nontuberculous mycobacteria, Talaromyces marneffei , and other intracellular pathogens. Current clinical management relies on continuous antimicrobial therapy, with no treatment offering sustained benefits. Here, we developed human chimeric autoantibody receptor (CAAR) T cells targeting autoreactive B cells expressing nAIGA B cell receptors (BCRs) using an IFN-γ receptor–irresponsive IFN-γ variant as bait. By exploiting a mouse model of nAIGA BCR-expressing B cell leukemia, we found that IFN-γ CAAR T cells lack off-target toxicity, including IFN-γ receptor cross-reactive toxicity and Fc-redirected toxicity. IFN-γ CAAR T cells substantially reduced circulating AIGAs secreted from target cells in vivo. Further, IFN-γ CAAR T cells effectively eliminated autoreactive B cells in ex vivo cultures of peripheral blood mononuclear cells from patients with nAIGAs. Together, these results demonstrate that IFN-γ CAAR T cells may be a promising strategy to ameliorate nAIGA-associated infections by eliminating autoreactive B cells.
- 9 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (107) , eadm8186
Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-γ
Neutralizing anti–interferon-γ (IFN-γ) autoantibodies (nAIGAs) impair IFN-γ–mediated immunity, predisposing patients with nAIGAs to infection by nontuberculous mycobacteria, Talaromyces marneffei , and other intracellular pathogens. Current clinical management relies on continuous antimicrobial therapy, with no treatment offering sustained benefits. Here, we developed human chimeric autoantibody receptor (CAAR) T cells targeting autoreactive B cells expressing nAIGA B cell receptors (BCRs) using an IFN-γ receptor–irresponsive IFN-γ variant as bait. By exploiting a mouse model of nAIGA BCR-expressing B cell leukemia, we found that IFN-γ CAAR T cells lack off-target toxicity, including IFN-γ receptor cross-reactive toxicity and Fc-redirected toxicity. IFN-γ CAAR T cells substantially reduced circulating AIGAs secreted from target cells in vivo. Further, IFN-γ CAAR T cells effectively eliminated autoreactive B cells in ex vivo cultures of peripheral blood mononuclear cells from patients with nAIGAs. Together, these results demonstrate that IFN-γ CAAR T cells may be a promising strategy to ameliorate nAIGA-associated infections by eliminating autoreactive B cells.
- 15 April 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (5) , 1275
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway
- 15 April 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (5) , 1275
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway